The Egyptian Journal of Internal Medicine

ORIGINAL ARTICLE
Year
: 2019  |  Volume : 31  |  Issue : 4  |  Page : 451--457

Noninvasive prediction of hepatitis C-associated hepatocellular carcinoma using circulating apolipoproteins


Hasan El Garem1, Gamal Esmat1, Rabab Salama1, Hanan Fouad2, Dina Sabry2, Yomna Mostafa3, Dalia Omran1, Heba Omar1 
1 Department of Endemic Medicine and Hepatogastroenterology, Faculty of Medicine, Cairo University, Cairo, Egypt
2 Department of Medical Biochemistry, Faculty of Medicine, Cairo University, Cairo, Egypt
3 Department of Hepatogastroenterology, Egypt Air Hospital, Cairo, Egypt

Correspondence Address:
MD, GCSRT Heba Omar
Faculty of Medicine, Cairo University, Cairo, 11652
Egypt

Background and aims Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. We investigated the potential usefulness of circulating apolipoproteins (Apo-A1 and Apo-A4) in HCC screening and diagnosis. Patients and methods We included 60 adult patients with hepatitis C virus-related chronic liver disease including HCC, in addition to 20 healthy controls. Patients were stratified into three equal groups, with 20 patients each: chronic hepatitis C, posthepatitis C cirrhosis (liver cirrhosis), and HCC. All patients and controls underwent full clinical assessment, laboratory investigations, and evaluation of candidate apolipoproteins by enzyme-linked immunoassay. Results Significantly higher Apo-A1 and Apo-A4 levels were detected in patients with HCC than in those with liver cirrhosis (P<0.001). Receiver operator characteristic curve showed that for HCC diagnosis, a cutoff of 78.6 mg/dl for Apo-A1 yielded 90% sensitivity and 100% specificity and a cutoff of 16.5 mg/dl for Apo-A4 yielded 85% sensitivity and 80% specificity. Furthermore, within HCC group, Apo-A1 was significantly higher in patients with small HCC (>2 cm) than those with large tumors (P=0.01). Lower Apo-A1 level correlated significantly with pylethrombosis (P=0.007). Conclusion Apo-A1 and Apo-A4 are novel biomarkers for HCC screening and diagnosis, with a special discriminative ability for Apo-A1 for those with small tumors and those with pylethrombosis.


How to cite this article:
El Garem H, Esmat G, Salama R, Fouad H, Sabry D, Mostafa Y, Omran D, Omar H. Noninvasive prediction of hepatitis C-associated hepatocellular carcinoma using circulating apolipoproteins.Egypt J Intern Med 2019;31:451-457


How to cite this URL:
El Garem H, Esmat G, Salama R, Fouad H, Sabry D, Mostafa Y, Omran D, Omar H. Noninvasive prediction of hepatitis C-associated hepatocellular carcinoma using circulating apolipoproteins. Egypt J Intern Med [serial online] 2019 [cited 2020 Oct 29 ];31:451-457
Available from: http://www.esim.eg.net/article.asp?issn=1110-7782;year=2019;volume=31;issue=4;spage=451;epage=457;aulast=El;type=0